Stock Upgrades Today: Top 5 Picks with the Strongest Upside Potential

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  28 Jul 2025
 

$NKE Nike is back in the spotlight after JPMorgan upgraded the stock to Overweight, projecting an 18% upside. Analysts were encouraged by Nike’s commitment to restoring a clean inventory channel and regaining pricing power by mid-2026. The company is executing a focused strategy to clear excess product, stabilize wholesale relationships, and rebuild its premium brand perception. With management reaffirming its roadmap to recovery, Nike looks poised for a multiyear rebound, making this upgrade particularly compelling.

$TXN Texas Instruments was upgraded to Outperform by Wolfe Research, citing signs of a cyclical recovery and a 24% potential upside. TI’s broad exposure to industrial and automotive sectors positions it well as macro headwinds ease and demand normalizes. The company’s disciplined capital allocation, solid dividend history, and strong market share in analog semiconductors provide a solid base for long-term growth.

$CLSK CleanSpark continues to gain momentum, receiving a fresh Buy rating from Ladenburg Thalmann while JPMorgan reaffirmed it as a top crypto pick. Unlike rivals chasing AI-fueled pivots, CleanSpark stuck with Bitcoin mining and is reaping the rewards. Rising hash rate, operational efficiency, and staying within its lane make CLSK a standout in a noisy crypto market. The dual backing from major analysts reinforces its upside potential, especially as the market begins to favor fundamentals over hype.

$PD PagerDuty got a bullish upgrade from TD Cowen based on its potential as an acquisition target. With strong automation tools, improving margins, and a sticky enterprise customer base, the company has quietly become an attractive buyout candidate. The upgrade reflects not just the fundamentals, but also the potential for a premium takeout valuation.

$RARE Ultragenyx was assumed at Buy by HC Wainwright, who sees the stock as an “intriguing buying opportunity.” Despite recent trial setbacks, the firm praised Ultragenyx’s diversified pipeline in rare diseases, calling it one of the most compelling long-term plays in biotech. Analysts are betting that the recent weakness is temporary, and the company’s depth of programs offers a strong recovery path.